Article Text

Download PDFPDF
Immortal time bias and infliximab-related mortality and malignancy incidence
  1. Laura Ellyn Targownik
  1. Correspondence to Dr Laura Ellyn Targownik, Section of Gastroenterology, University of Manitoba, 805g-715 McDermot Ave, Winnipeg R3N 0V6, Canada; targowni{at}

Statistics from

In this intriguing article, Fidder et al report on the long-term follow-up of a cohort of subjects with inflammatory bowel disease (IBD) managed at a tertiary care institution.1 The authors conclude that IBD patients exposed to infliximab are at no higher risk for mortality or being diagnosed as having malignancy than controls with no prior infliximab exposure. These results would appear to confirm the safety of this drug in the treatment of IBD, as suggested by other studies of IBD cohorts followed over the long-term. However, it appears that this study may contain significant biases which …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • PostScript
    HH Fidder K van de Steen G van Assche P Rutgeerts S Vermeire